ANNX
Price
$2.71
Change
+$0.19 (+7.54%)
Updated
Jun 12, 03:34 PM (EDT)
Capitalization
276.48M
67 days until earnings call
ERAS
Price
$1.53
Change
+$0.01 (+0.66%)
Updated
Jun 12, 03:49 PM (EDT)
Capitalization
430.6M
56 days until earnings call
Interact to see
Advertisement

ANNX vs ERAS

Header iconANNX vs ERAS Comparison
Open Charts ANNX vs ERASBanner chart's image
Annexon
Price$2.71
Change+$0.19 (+7.54%)
Volume$2.21K
Capitalization276.48M
Erasca
Price$1.53
Change+$0.01 (+0.66%)
Volume$360
Capitalization430.6M
ANNX vs ERAS Comparison Chart
Loading...
ANNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ERAS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ANNX vs. ERAS commentary
Jun 13, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ANNX is a Buy and ERAS is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 13, 2025
Stock price -- (ANNX: $2.52 vs. ERAS: $1.52)
Brand notoriety: ANNX and ERAS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ANNX: 44% vs. ERAS: 55%
Market capitalization -- ANNX: $276.48M vs. ERAS: $430.6M
ANNX [@Biotechnology] is valued at $276.48M. ERAS’s [@Biotechnology] market capitalization is $430.6M. The market cap for tickers in the [@Biotechnology] industry ranges from $353.76B to $0. The average market capitalization across the [@Biotechnology] industry is $2.44B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ANNX’s FA Score shows that 1 FA rating(s) are green whileERAS’s FA Score has 1 green FA rating(s).

  • ANNX’s FA Score: 1 green, 4 red.
  • ERAS’s FA Score: 1 green, 4 red.
According to our system of comparison, ANNX is a better buy in the long-term than ERAS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ANNX’s TA Score shows that 5 TA indicator(s) are bullish while ERAS’s TA Score has 5 bullish TA indicator(s).

  • ANNX’s TA Score: 5 bullish, 3 bearish.
  • ERAS’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, ANNX is a better buy in the short-term than ERAS.

Price Growth

ANNX (@Biotechnology) experienced а +3.70% price change this week, while ERAS (@Biotechnology) price change was -0.65% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +6.07%. For the same industry, the average monthly price growth was +16.42%, and the average quarterly price growth was +7.21%.

Reported Earning Dates

ANNX is expected to report earnings on Aug 18, 2025.

ERAS is expected to report earnings on Aug 07, 2025.

Industries' Descriptions

@Biotechnology (+6.07% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ERAS($431M) has a higher market cap than ANNX($276M). ERAS YTD gains are higher at: -39.442 vs. ANNX (-50.877). ANNX (-151.48M) and ERAS (-153.28M) have comparable annual earnings (EBITDA) . ANNX (312M) and ERAS (298M) have equal amount of cash in the bank . ANNX has less debt than ERAS: ANNX (29M) vs ERAS (51.9M). ANNX (0) and ERAS (0) have equivalent revenues.
ANNXERASANNX / ERAS
Capitalization276M431M64%
EBITDA-151.48M-153.28M99%
Gain YTD-50.877-39.442129%
P/E RatioN/AN/A-
Revenue00-
Total Cash312M298M105%
Total Debt29M51.9M56%
TECHNICAL ANALYSIS
Technical Analysis
ANNXERAS
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
83%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
82%
Momentum
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
78%
MACD
ODDS (%)
N/A
Bullish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
86%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
77%
Advances
ODDS (%)
Bullish Trend 24 days ago
83%
N/A
Declines
ODDS (%)
N/A
Bearish Trend 2 days ago
88%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
83%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
ANNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ERAS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FHETX16.73N/A
N/A
Fidelity Advisor Real Estate M
CHUCX25.52N/A
N/A
Alger Global Equity C
TRPGX14.97-0.03
-0.20%
Nuveen Core Equity Premier
SDLAX18.90-0.04
-0.21%
SEI Dynamic Asset Allocation A (SIIT)
AWSIX16.86-0.05
-0.30%
Invesco Global Core Equity R5

ANNX and

Correlation & Price change

A.I.dvisor indicates that over the last year, ANNX has been loosely correlated with IDYA. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if ANNX jumps, then IDYA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ANNX
1D Price
Change %
ANNX100%
-4.55%
IDYA - ANNX
46%
Loosely correlated
-3.14%
ERAS - ANNX
45%
Loosely correlated
-5.59%
CRNX - ANNX
44%
Loosely correlated
-2.27%
TRML - ANNX
44%
Loosely correlated
+0.50%
STOK - ANNX
44%
Loosely correlated
+1.23%
More

ERAS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ERAS has been loosely correlated with RVMD. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if ERAS jumps, then RVMD could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ERAS
1D Price
Change %
ERAS100%
-5.59%
RVMD - ERAS
57%
Loosely correlated
-2.83%
XNCR - ERAS
57%
Loosely correlated
-2.26%
APGE - ERAS
53%
Loosely correlated
+1.00%
LRMR - ERAS
52%
Loosely correlated
+6.53%
IMNM - ERAS
51%
Loosely correlated
-0.84%
More